 |
|
The Hsp90-Antifungal Combo, please: Compromising fungi in the immunocompromised
February 10, 2009Even the most drug-resistant fungi can be eradicated in multiple in vitro and in vivo models using a lethal combination of an antifungal agent and inhibition of the heat shock protein Hsp90, according to a new study by Whitehead Institute and University of Toronto researchers. The findings could enable development of novel antifungal therapies for patients with compromised immune systems.
Immunocompromised individuals--including HIV, chemotherapy, and organ transfer patients--with resistant fungal infections suffer mortality rates ranging from 50 to 90 percent.
"Being a pediatric oncologist, I have seen many unfortunate patients die from resistant fungal infections," says Luke Whitesell, a scientist in the lab of Whitehead Member Susan Lindquist. "It's incredibly frustrating to see a child with their cancer in remission being slowly eaten alive by a fungus like Aspergillus, and there's nothing you can do about it."
The development of effective antifungal drugs is limited by humans' close evolutionary relationship with fungi, and, in recent years, fungi's ever-evolving resistance to existing drugs. Former Lindquist postdoctoral researcher and lead author of this study, Leah Cowen, explains: "The drugs just don't wipe out the infection. So you wind up with a small population of fungi living in a host that is exposed to the drug for a long time, which favors evolution of drug resistance."
Previous studies suggested that Hsp90, which is found in both fungi and humans, plays a vital role in the evolution of drug resistance. In this most recent study, which appears in the February 24 issue of the Proceedings of the National Academy of Science (PNAS), Whitehead researchers tested Hsp90 inhibitors in combination with common antifungal drugs in an attempt to block the growth of Candida albicans and Aspergillus fumigatus, two of the most prevalent and lethal species that cause fungal infections in humans.
The researchers found that when antifungals or Hsp90 inhibitors are used individually, they are ineffective; however, when paired they form a deadly duo.
"When you combine the two, you reduce Hsp90 function enough that the fungi can no longer mount the crucial stress responses to antifungals required for survival," says Cowen. "So you cripple the fungus by severely compromising its stress responses."
According to Lindquist, "This is an entirely new strategy for making fungi susceptible to preexisting drugs and for preventing fungi from deploying the resistance mechanisms, which they have evolved against those compounds. It could make the difference between life and death."
Because Hsp90 is highly conserved, finding a compound to turn off Hsp90 in fungi, but not in humans, is a significant hurdle scientists must overcome. In addition, current Hsp90 inhibitors are toxic in mice with resistant fungal infections. To find promising Hsp90 inhibitors for antifungal therapy, Lindquist's lab has received a grant from the Molecular Libraries Probe Center Network (MLPCN) Program of the National Institutes of Health. The grant will allow researchers to screen large numbers of compounds in the search for potential fungus-selective Hsp90 inhibitors.
Still, even if the screen is successful, the battle between humans and fungi is not over.
"Eventually, like most drugs, Hsp90 inhibitors too, will become subject to resistance," suggests Lindquist, who is also a Howard Hughes Medical Institute investigator and professor of biology at MIT. "But in the meantime, these inhibitors will open a very large window of opportunity for individuals with resistant fungal infections."
Whitehead Institute for Biomedical Research
The development of effective antifungal drugs is limited by humans' close evolutionary relationship with fungi, and, in recent years, fungi's ever-evolving resistance to existing drugs. Former Lindquist postdoctoral researcher and lead author of this study, Leah Cowen, explains: "The drugs just don't wipe out the infection. So you wind up with a small population of fungi living in a host that is exposed to the drug for a long time, which favors evolution of drug resistance."
Previous studies suggested that Hsp90, which is found in both fungi and humans, plays a vital role in the evolution of drug resistance. In this most recent study, which appears in the February 24 issue of the Proceedings of the National Academy of Science (PNAS), Whitehead researchers tested Hsp90 inhibitors in combination with common antifungal drugs in an attempt to block the growth of Candida albicans and Aspergillus fumigatus, two of the most prevalent and lethal species that cause fungal infections in humans.
The researchers found that when antifungals or Hsp90 inhibitors are used individually, they are ineffective; however, when paired they form a deadly duo.
"When you combine the two, you reduce Hsp90 function enough that the fungi can no longer mount the crucial stress responses to antifungals required for survival," says Cowen. "So you cripple the fungus by severely compromising its stress responses."
According to Lindquist, "This is an entirely new strategy for making fungi susceptible to preexisting drugs and for preventing fungi from deploying the resistance mechanisms, which they have evolved against those compounds. It could make the difference between life and death."
Because Hsp90 is highly conserved, finding a compound to turn off Hsp90 in fungi, but not in humans, is a significant hurdle scientists must overcome. In addition, current Hsp90 inhibitors are toxic in mice with resistant fungal infections. To find promising Hsp90 inhibitors for antifungal therapy, Lindquist's lab has received a grant from the Molecular Libraries Probe Center Network (MLPCN) Program of the National Institutes of Health. The grant will allow researchers to screen large numbers of compounds in the search for potential fungus-selective Hsp90 inhibitors.
Still, even if the screen is successful, the battle between humans and fungi is not over.
"Eventually, like most drugs, Hsp90 inhibitors too, will become subject to resistance," suggests Lindquist, who is also a Howard Hughes Medical Institute investigator and professor of biology at MIT. "But in the meantime, these inhibitors will open a very large window of opportunity for individuals with resistant fungal infections."
Whitehead Institute for Biomedical Research
Targeting helpers of heat shock proteins could help treat cancer, cardiovascular disease
Dissecting how heat shock protein 90 gets steroid receptors into shape to use hormones like estrogen and testosterone could lead to targeted therapies for hormone-driven cancers, such as breast and prostate, that need them as well, Medical College of Georgia researchers say.
Researchers aim to over-stress already taxed mantle cell lymphoma cells
Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.
Sidestepping cancer's chaperone
Cancerous tumors are wildly unfavorable environments. Struggling for oxygen and nutrients while being bombarded by the body's defense systems, tumor cells in fact require sophisticated adaptations to survive and grow.
First high-res 3D structures of mammalian HSP90 protein solved
Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated in immune diseases such as sepsis, AIDS and certain cancers.
Chemical genomic screening identifies novel therapeutic strategies for cancer
A sophisticated new chemical genetic screening strategy that serves as a tool for identifying anticancer compounds may significantly enhance the drug discovery process.
More Hsp90 Inhibitors Current Events and Hsp90 Inhibitors News Articles
|
Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors by La Merie S.L. (Author) The Competitive Intelligence Report Heat shock protein 90 (Hsp90) Inhibitors updated as of May 2008 provides a competitor analysis in the development pipeline of novel small molecules targeting the heat shock protein 90 (Hspo90) chaperone for treatment of cancer. Among the companies active in t he R&D field ofHsp90 inhibitors are Kosan Bioscience, MedImmune and many others. The report includes a compilation of current active projects in research and development of Hsp90 Inhibitors. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Therapeutic area, Indication, R&D Stage and additional comments with a hyperlink... |
| © 2009 BrightSurf.com |